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Abstract
 
Coronary artery thrombosis is often initiated by abrupt disruption of the atherosclerotic plaque
and activation of platelets on the subendothelial layers in the disrupted plaque. The extracellu-
lar matrix protein collagen is the most thrombogenic constituent of the subendothelial layer;
therefore, a selective inhibition of the collagen activation pathway in platelets may provide
strong antithrombotic protection while preserving other platelet functions. Here we demon-
strate that treatment of mice with a monoclonal antibody against the activating platelet collagen
receptor glycoprotein VI (GPVI; JAQ1) results in specific depletion of the receptor from circu-
lating platelets and abolished responses of these cells to collagen and collagen-related peptides
(CRPs). JAQ1-treated mice were completely protected for at least 2 wk against lethal throm-
boembolism induced by infusion of a mixture of collagen (0.8 mg/kg) and epinephrine (60
 
m
 
g/ml). The tail bleeding times in JAQ1-treated mice were only moderately increased com-
pared with control mice probably because the treatment did not affect platelet activation by
other agonists such as adenosine diphosphate or phorbol myristate acetate. These results suggest
that GPVI might become a target for long-term prophylaxis of ischemic cardiovascular diseases
and provide the first evidence that it is possible to specifically deplete an activating glycoprotein
receptor from circulating platelets in vivo.
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Introduction
 
Platelet aggregation is a key mechanism for normal hemo-
stasis limiting blood loss after tissue trauma (1, 2) but may
lead to arterial occlusion in the setting of atherosclerosis and
precipitate diseases such as myocardial infection (3, 4). Arte-
rial thrombosis is often initiated by abrupt disruption of the
atherosclerotic plaque and deposition and activation of
platelets on the subendothelial layers (4, 5). Although sev-
eral of the macromolecular components of the subendothe-
lial layer such as laminin, fibronectin, and von Willebrand
factor (vWf)
 
1
 
 all provide a suitable substrate for platelet ad-
hesion, fibrillar collagen is considered the most thrombo-
genic constituent of the vascular subendothelium, as it not
only supports platelet adhesion but is also a strong activator
of platelets (6, 7). The interaction between platelets and
collagen involves first adhesion and, subsequently, activa-
tion leading to second phase adhesion, secretion, and ulti-
mately aggregation (8, 9). Besides glycoprotein (GP)Ib-
IX-V, which indirectly interacts with collagen via vWF (10),
several collagen receptors have been identified on platelets,
including integrin 
 
a
 
2
 
b
 
1 
 
(11), and the nonintegrin GPVI
(12). It is presently accepted that integrin 
 
a
 
2
 
b
 
1 
 
is the major
receptor supporting platelet adhesion to collagen, whereas
GPVI mediates activation (13–15). The recent cloning of
human and mouse GPVI showed that this receptor is a 60–
65-kD type I transmembrane glycoprotein belonging to the
immunoglobulin superfamily (16, 17) that forms a complex
with the FcR 
 
g
 
-chain at the cell surface in human and
mouse platelets (14, 15, 18). Signaling through GPVI oc-
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 ADP, adenosine diphosphate; CRP,
collagen-related peptide; ECL, enhanced chemiluminescence; GP, glyco-
protein; prp, platelet-rich plasma; RT, room temperature; vWF, von
Willebrand factor. 
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curs via a similar pathway to that used by immunoreceptors
(19) as revealed by the tyrosine phosphorylation of the FcR
 
g
 
-chain immunoreceptor tyrosine–based activation motif
(ITAM) by an src-like kinase (20, 21). GPVI-deficient pa-
tients suffer from a mild bleeding diathesis, and their plate-
lets show severely impaired responses to collagen (12, 22).
Furthermore, platelets from FcR 
 
g
 
-chain–deficient mice,
which lack GPVI (15), also fail to aggregate in response to
collagen (14, 19), but major bleeding has not been reported
to occur in these mice.
In this study we investigated the antithrombotic effect of
the first anti–(mouse) GPVI Ab (JAQ1; [15]). We show
that pretreatment with JAQ1 leads to irreversible depletion
of GPVI on circulating platelets resulting in abolished re-
sponses of the cells to collagen and, consequently, pro-
found and long-lasting protection from mortality in a
model of collagen-dependent intravascular thrombosis.
The tail bleeding times in GPVI-depleted mice were only
moderately increased compared with the controls, probably
because other activation pathways were preserved in these
platelets. These results provide the first evidence that GPVI
might serve as an attractive target for long-term prophylaxis
of cardiovascular diseases.
 
Materials and Methods
 
Animals.
 
Specific pathogen-free mice (NMRI) 6–10 wk of
age were obtained from Charles River Laboratories and kept in
our animal facilities.
 
Chemicals.
 
Anesthetic drugs xylazine (Rompun
 
®
 
) and keta-
mine (Imalgene 1000
 
®
 
) were from Bayer and Mérial, respec-
tively. Immobilized papain (Pierce Chemical Co.), high molecu-
lar weight heparin, adenosine diphosphate (ADP), phorbol
12-myristate 13-acetate (PMA; all from Sigma-Aldrich), FITC-
labeled annexin V (Boehringer), and collagen (Kollagenreagent
Horm; Nycomed) were purchased. Collagen-related peptide
(CRP; GKO-(GPO)
 
10
 
-GKOG; single letter amino acid code
where O 
 
5
 
 hydroxyproline) and convulxin were provided by
S.P. Watson (University of Oxford, Oxford, UK). FITC-labeled
convulxin was a gift from M. Jandrot-Perrus (INSERM, Paris,
France).
 
Abs.
 
The rat anti–mouse P-selectin mAb RB40.34 was pro-
vided by D. Vestweber (University of Münster, Münster, Ger-
many). Polyclonal rabbit Abs to human fibrinogen and vWF were
purchased from Dako and were modified in our laboratories.
Rabbit anti-FITC–horseradish peroxidase (HRP) was from Dako.
mAbs against the integrin 
 
a
 
2 and 
 
b
 
1 subunits were from BD
PharMingen. All other Abs were generated, produced, and modi-
fied in our laboratories and have been described (23, 24).
 
 
 
Modifi-
cation of Abs: Fab fragments from JAQ1 were generated by 12-h
incubation of 10 mg/ml mAb with immobilized papain (Pierce
Chemical Co.), and the preparations were then applied to an im-
mobilized protein A column followed by an immobilized protein
G column (Amersham Pharmacia Biotech) to remove Fc frag-
ments and any undigested IgG. The purity of the Fab fragments
was checked by SDS-PAGE and silver staining of the gel. F(ab
 
9
 
)
 
2
 
fragments from JON/A (anti–mouse GPIIb/IIIa) were generated
as described (24).
 
Platelet Preparation and Counting.
 
Mice were bled under ether
anesthesia from the retroorbital plexus. Blood was collected in a
tube containing 10% (vol/vol) 0.1 M sodium citrate or 7.5 U/ml
heparin, and platelet-rich plasma (prp) was obtained by centrifu-
gation at 300 
 
g
 
 for 10 min at room temperature (RT). For deter-
mination of platelet counts, blood (20 
 
m
 
l) was obtained from the
retroorbital plexus of anesthetized mice using siliconized micro-
capillaries and immediately diluted 1:100 in Unopette kits (Bec-
ton Dickinson). The diluted blood sample was allowed to settle
for 20 min in an Improved Neubauer haemocytometer (Supe-
rior), and platelets were counted under a phase contrast micro-
scope at 
 
3
 
400 magnification.
 
Immunoblotting.
 
Platelets (3 
 
3 
 
10
 
8
 
) were washed three times
with PBS and subsequently solubilized in 0.3 ml lysis buffer
(Tris-buffered saline containing 20 mM Tris/HCl, pH 8, 150
mM NaCl, 1 mM EDTA, 1 mM phenylmethylsulfonyl fluoride,
2 
 
m
 
g/ml aprotinin, 0.5 
 
m
 
g/ml leupeptin, and 0.5% Nonidet
P-40; all from Boehringer) for 30 min at 4
 
8
 
C. Cell debris was re-
moved by centrifugation (15,000 
 
g
 
, 10 min) and the whole-cell
extract was run on an SDS-PAGE gel under nonreducing condi-
tions and transferred onto a PVDF membrane. The membrane
was first incubated with 5 
 
m
 
g/ml FITC-labeled primary Ab fol-
lowed by rabbit anti-FITC–HRP (1 
 
m
 
g/ml). Proteins were visu-
alized by enhanced chemiluminescence (ECL).
 
Two-dimensional Electrophoresis.
 
Washed platelets were pellet-
ted and resuspended in 20 mM Tris, pH 7.5, 2 mM EDTA, and
0.25 M sucrose. Platelets were solubilized by addition of 4 vol of
8.75 M urea, 2.5 M thiourea, 25 mM dithiothreitol (DTT),
1.25% Triton X-100, and 0.75% ampholytes 3-10. Two-dimen-
sional gel electrophoresis (2D-E) was carried out as described
(25). In brief, IEF was carried out with commercially available
immobilized pH gradient (linear pH gradient 3–10, 7 cm length),
using the Protean IEF Cell apparatus (Bio-Rad Laboratories).
The gels were rehydrated in the presence of the samples (platelet
lysates corresponding to 5 
 
3
 
 10
 
7
 
 platelets) for 16 h and focused
for 20.000 Vh. After IEF, the gel strips were incubated at RT in
solutions containing DTT and then iodoacetamide, as described
(26). The gels were then subjected to the second-dimensional
run and silver stained.
 
Aggregometry.
 
To determine platelet aggregation, light trans-
mission was measured using prp (200 
 
m
 
l with 0.5 
 
3
 
 10
 
6
 
 platelets/
 
m
 
l). Transmission was recorded on a Fibrintimer 4 channel aggre-
gometer (APACT Laborgeräte und Analysensysteme) over 10
min and was expressed as arbitrary units with 100% transmission
adjusted with plasma. Platelet aggregation was induced by addi-
tion of collagen (5–50 
 
m
 
g/ml), PMA (50 ng/ml), or ADP (10
 
m
 
M).
 
Flow Cytometry.
 
Heparinized whole blood was diluted 1:30
with modified Tyrodes-Hepes buffer (134 mM NaCl, 0.34 mM
Na
 
2
 
HPO
 
4
 
, 2.9 mM KCl, 12 mM NaHCO
 
3
 
, 20 mM Hepes, 5
mM glucose, and 1 mM MgCl
 
2
 
, pH 6.6) and left for 30 min at
37
 
8
 
C before stimulation. Samples were stimulated with the indi-
cated concentrations of ADP or CRP for 2 min at RT, stained
with fluorophore-labeled mAbs for 10 min at RT, and directly
analyzed on a FACScan™ (Becton Dickinson). Flow cytometric
analysis of annexin V-FITC binding to resting and activated
(combination of 50 
 
m
 
g/ml collagen and 0.01 U/ml thrombin)
platelets was measured according to the instructions of the manu-
facturer.
 
In Vivo Experiments.
 
Abs (in 200 
 
m
 
l PBS) were injected in-
traperitoneally. Thromboembolism induced by collagen and epi-
nephrine: mice were anesthetized by intraperitoneal injection of
150 
 
m
 
l of a mixture of 0.08% xylazine base (Rompun; Bayer) and
1.6% ketamine (Imalgene 1000; Mérial). Anesthetized mice re-
ceived a mixture of collagen (0.8 mg/kg) and epinephrine (60
 
m
 
g/kg) injected into the jugular vein (27). The incisions of sur- 
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viving mice were stitched, and they were allowed to recover.
Necroscopy and histological studies were performed on lungs
fixed in 4% formaldehyde and paraffin sections were stained with
hematoxylin/eosin. Bleeding time experiments: mice were anes-
thetized and 3 mm of tail tip was amputated with a scalpel. The
tail was then blotted with filter paper every 15 s until the paper
was no longer blood stained (28).
 
 
 
Where necessary, bleeding was
manually stopped at the 10 min time point to prevent death. Ex-
periments were conducted in accordance to the regulations of the
local authorities.
 
Immunohistochemistry.
 
Acetone-fixed cryosections (6 
 
m
 
m)
were blocked (5% normal goat serum, 5 mg/ml BSA in PBS) for
30 min at RT. HRP-conjugated p0p1 (anti–mouse GPIb-IX
[23]) was added at a final concentration of 2 
 
m
 
g/ml for 90 min
and the 3-amino-9-ethyl-carbazole (AEC) substrate was added
after the three washing steps. The sections were then counter-
stained with hematoxylin
 
.
Platelet Adhesion.
 
Collagen (2 
 
m
 
g) in 100 
 
m
 
l PBS was immo-
bilized on F96-MaxiSorp plates (Nunc) at 4
 
8
 
C overnight. The
plates were then saturated with 1 mg/ml BSA in PBS for 3 h at
37
 
8
 
C and washed with PBS. Washed platelets in Tyrode’s-albu-
min buffer (10
 
6
 
/well) were incubated in the wells for up to 45
min. The plates were washed three times with PBS and then in-
cubated with HRP-labeled anti–GPIb-IX (p0p1) for 30 min at
RT, and 3,3,5,5-tetramethylbenzidine (TMB) was added to each
well after three washing steps. The reaction was stopped by addi-
tion of 2 N H
 
2
 
SO
 
4 
 
after 10 min. Absorbance at 450 nm was re-
corded on a Multiskan MCC/340 (Labsystems).
 
Results
 
We recently reported the generation of the first mAb
against mouse GPVI (JAQ1, rat IgG2a) and demonstrated
that JAQ1 has a significant but limited inhibitory effect on
collagen-induced platelet aggregation in vitro (15, 29). In
this study, we investigated the antithrombotic effects of
JAQ1 in vivo. Injection of JAQ1 (100 
 
m
 
g) caused mild and
transient thrombocytopenia with a maximum drop of
platelet counts of 
 
z
 
34 
 
6
 
 7.4% on day 1 and a return to
normal after 72 h, where they remained for at least 11
more days (Fig. 1 a). Injection of higher (200 
 
m
 
g) or lower
(50 
 
m
 
g) doses had comparable effects on platelet counts
(Fig. 1 a). The transient drop of platelet counts was not Fc
dependent, as Fab fragments of JAQ1 had similar effects
(Fig. 1 b). JAQ1-treated mice did not show any signs of
anaphylactic reactions as known to be induced by anti-
GPIIb/IIIa mAbs (30) and did not develop spontaneous
bleeding for at least 3 wk. JAQ1 was immunohistochemi-
cally detectable on splenic and bone marrow–derived
megakaryocytes 3 h after Ab injection, demonstrating that
the mAb reached these cells in both organs (not shown).
 
JAQ1 Treatment Abolishes Platelet Responses to Collagen
and CRPs Ex Vivo for at Least 2 Wk.
 
The effect of JAQ1
on circulating platelets was studied ex vivo at different time
points after Ab injection. The basal surface expression of
the major GP receptors GPIIb/IIIa and GPIb-IX-V, CD9
and integrin 
 
a
 
2
 
b
 
1
 
 was unchanged compared with control
platelets at 3, 7, and 14 d after Ab injection (Table I). At no
time after Ab injection did circulating platelets show any
signs of activation, as demonstrated by the lack of surface
bound fibrinogen and surface-expressed P-selectin (Table
I). On days 3, 7, and 14, platelets from JAQ1-treated mice
were resistant towards activation with the CRP (up to 30
 
m
 
g/ml), which is known to be a strong GPVI-specific
platelet agonist (31; Fig. 2 a). In contrast, ADP induced
normal activation (fibrinogen binding) of these platelets.
Furthermore, platelets from JAQ1-treated mice were com-
pletely resistant to activation with collagen at concentra-
tions of up to 50 
 
m
 
g/ml ex vivo, and this profound inhibi-
tory effect also lasted for at least 14 d upon a single
injection of 100 
 
m
 
g JAQ1 (Fig. 2 b). In contrast to col-
lagen, ADP and PMA induced normal aggregation of these
Figure 1. JAQ1 induces transient thrombocytopenia. Mice received
purified IgG (a) or Fab fragments (b) of the indicated mAb intraperito-
neally in 200 ml sterile PBS. Platelet counts were determined at the indi-
cated times using an improved Neubauer hemocytometer. Results are ex-
pressed as the mean platelet count 6 SD for groups of each six mice.
 
Table I.
 
Expression of Glycoproteins and Surface-bound Fibrinogen 
on Platelets from JAQ1-treated Mice
 
Control JAQ1 3 d JAQ1 7 d JAQ1 14 d
 
GPIIb/IIIa
 
321.3 
 
6 
 
9.7 318.1 
 
6 
 
9.4 328.7 
 
6 
 
9.1 325.3 
 
6 
 
9.8
 
GPIb-IX
 
278.9 
 
6 
 
16.8 275.4 
 
6 
 
18.0 269.5 
 
6 
 
15.9 273.1 
 
6 
 
11.4
 
GPV
 
165.4 
 
6 
 
10.9 163.3 
 
6 
 
14.1 169.1 
 
6 
 
15.3 158.1 
 
6 
 
10.5
 
CD9
 
543.8 
 
6 
 
15.8 554.3 6 14.6 549.5 6 19.6 557.0 6 13.0
GPIa (a2) 38.2 6 6.7 40.3 6 6.5 35.2 6 7.8 36.7 6 6.2
Fibrinogen 14.1 6 1.7 15.0 6 1.4 14.3 6 1.5 14.4 6 1.5
P-selectin 6.2 6 0.8 6.5 6 0.8 6.7 6 0.8 6.0 6 1.1
Diluted whole blood from the indicated mice was incubated with
FITC-labeled Ab at saturating concentrations for 15 min at RT and
platelets were analyzed directly. Results are expressed as mean log
fluorescence  6  SD for six mice per group.462 Long-term Antithrombotic Protection by In Vivo Depletion of GPVI
Figure 2. Platelets from JAQ1-treated mice do not respond to CRP
and collagen. (a) Two-color flow cytometric analysis of platelets from
JAQ1-treated or control mice 3 d after Ab injection. Diluted whole
blood was stimulated with 10 mM ADP or 10 mg/ml CRP for 2 min and
subsequently incubated with antifibrinogenFITC and anti–P-selectinPE Abs
for 10 min at RT and analyzed directly. Platelets were gated by FSC/SSC
characteristics and Fl3 intensity (anti–mouse GPIb a PE/Cy5). The data
shown are representative of six mice per group. Similar results were ob-
tained on days 7 and 14 after Ab injection. (b) Heparinized prp from the
indicated mice was stimulated with collagen (50 mg/ml), ADP (10 mM),
or PMA (50 ng/ml). Light transmission was recorded on a Fibrintimer 4
channel aggregometer. (c) Heparinized prp from control mice was incu-
bated with stirring in the presence of irrelevant rat IgG2a (20 mg/ml; s)
or JAQ1 (20 mg/ml; ,) for 5 min before the addition of the indicated
concentrations of collagen. In parallel, prp from JAQ1-treated mice was
tested (h). Results are expressed as the maximum (max.) platelet aggrega-
tion 6 SD for groups of each six mice.
Figure 3. GPVI is not detectable in platelets from JAQ1-treated mice
for at least 2 wk. (a) Whole platelet proteins were separated by SDS-
PAGE under nonreducing conditions and immunoblotted with FITC-
labeled JAQ1 (anti-GPVI) or EDL1 (anti-GPIIIa). Bound mAb was de-
tected by HRP-labeled rabbit anti-FITC and ECL. (b) Washed platelets
from control, FcR g-chain–deficient (FcRg2/2) and JAQ1-treated (day
7) mice were stimulated with 10 mg/ml convulxin (Cvx). Control plate-
lets were preincubated with irrelevant rat IgG2a or JAQ1 (20 mg/ml) for
5 min before the addition of Cvx. (c) Washed platelets from the indicated
mice were incubated with FITC-labeled convulxin (5 mg/ml) for 15 min
at RT and then analyzed on a FACScan™ (Becton Dickinson). The data
shown are representative of six mice per group.
platelets, indicating that JAQ1 specifically blocked GPVI-
dependent platelet activation pathways whereas other func-
tions were not affected. In vitro, saturating concentrations
of JAQ1 (20 mg/ml) only displayed a limited inhibitory ef-
fect on collagen-induced platelet aggregation which could
be overcome when collagen concentrations higher than
z7 mg/ml were used (Fig. 2 c), confirming earlier results
(29).
JAQ1 Induces the Loss of GPVI on Circulating Platelets In
Vivo. The discrepancy between the inhibitory effect of
JAQ1 on collagen-induced aggregation in vitro and ex
vivo was surprising and suggested that mechanisms other463 Nieswandt et al.
than pure blockage of an epitope on GPVI must be in-
volved. Therefore, the next step was to test platelets from
JAQ1-treated mice for the presence of GPVI in a Western
blot analysis of whole cell lysates. As shown in Fig. 3 a,
GPVI was not detectable in platelets from JAQ1-treated
mice for at least 14 d upon a single injection of JAQ1,
whereas GPIIIa was present in normal amounts at any time
point. In contrast, in all mice tested, new platelets express-
ing functional GPVI were detectable after 28 d. To further
assess the absence of GPVI on platelets from JAQ1-treated
mice, we used the GPVI-specific snake venom toxin con-
vulxin (32). As shown in Fig. 3 b, convulxin did not in-
duce aggregation of platelets from JAQ1-treated mice on
day 3, 7, and 14, whereas it induced aggregation of control
platelets in the presence or absence of saturating amounts of
JAQ1. Furthermore, flow cytometric analysis demonstrated
that FITC-labeled convulxin did not bind to platelets from
JAQ1-treated mice (Fig. 3 c). Finally, the absence of an
z60 kD protein with an isoelectric point of 5.6 in the
platelets from JAQ1-treated mice was confirmed by two-
dimensional gel electrophoresis (Fig. 4). Together, these
results strongly suggested that GPVI had been irreversibly
inactivated and removed from these platelets in vivo.
JAQ1-induced GPVI Loss Occurs Rapidly In Vivo and Is Fc
Independent. To examine the mechanisms underlying the
loss of GPVI, mice were injected with biotinylated JAQ1
and the amount of surface-bound mAb was determined
flow cytometrically ex vivo at early time points after injec-
tion. Interestingly, as soon as 6 h after injection only very
low levels of surface-bound JAQ1 were detectable and the
signals further decreased to control after 24 and 48 h (Fig. 5
a), whereas JAQ1FITC and CvxFITC bound to the platelets at
no time point. These data suggested that the JAQ1–GPVI
complex had been cleared from the surface of those plate-
lets within 6 h. In contrast, platelets from mice injected
with a biotinylated mAb against GPV (24) constantly
yielded positive staining with FITC-labeled streptavidin
(Fig. 5 b). In the next step, we tested whole cell lysates
from platelets of JAQ1-treated mice for the presence of
GPVI and the biotinylated mAb. As shown in Fig. 5 c,
JAQ1 was strongly detectable in platelets 6 h after injec-
tion, whereas signals markedly decreased at 24 h and even
more at 48 h. A similar picture was found for GPVI,
strongly suggesting that the JAQ1–GPVI complex had be-
come internalized and was degraded within 2 d. In contrast
to its in vivo effects, JAQ1 did not induce any detectable
downregulation of surface GPVI within 6 h incubation at
378C on washed platelets or in whole blood (heparinized
or citrated), indicating that a second signal may be required
to induce this effect and that this signal is absent in vitro
(Fig. 5 a).
To determine whether the Fc part of JAQ1 or its diva-
lent form is required for internalization/degradation of
GPVI, mice received 100 mg Fab fragments of the mAb
and the platelets were tested for the presence of GPVI after
48 h. As shown in Fig. 5 d, the Fab fragments, like the in-
tact IgG, induced the complete loss of GPVI from circulat-
ing platelets and the cells were completely resistant towards
activation with CRP, collagen, or convulxin.
GPVI-depleted Platelets Display Reduced Adhesion to
Collagen and Abolished Collagen-dependent Procoagulant Ac-
tivity. It is currently thought that GPVI is the platelet col-
lagen receptor for activation, whereas integrin a2b1 and
GPIb-V-IX (via vWF) mediate adhesion. As shown before
Figure 4. Absence of a  z60-kD protein in platelets
from JAQ1-treated mice. Whole cell lysates of platelets
from control and JAQ1-treated (day 7) mice were sub-
jected to two-dimensional gel electrophoresis and the gels
were silver stained. First dimension: IEF (linear pH gradi-
ent 3–10). Second dimension: SDS-PAGE under reducing
conditions. The molecular weight marker is shown on the
right. The position of the z60-kD protein (pI: z5.6) that
is absent in platelets from JAQ1-treated mice is indicated
by arrows.464 Long-term Antithrombotic Protection by In Vivo Depletion of GPVI
(Table I), the basal surface expression of both receptors was
not influenced by the JAQ1 treatment. Further experi-
ments demonstrated that platelets from JAQ1-treated mice
bound normal levels of vWF in the presence of botrocetin,
and thrombin induced normal activation of b1-integrins, as
assessed with the mAb 9EG7, which specifically recognizes
the activated form of the b1 subunit (33; Fig. 6 a). In the
next step, the adhesion of platelets from JAQ1-treated mice
Figure 5. JAQ1 induces internalization of GPVI in vivo Fc independently.
Mice were injected with 100 mg biotinylated JAQ1 or DOM1 (anti-GPV)
and platelets were analyzed at the indicated time points. (a) Flow cytometric
analysis of platelets from JAQ1-treated or control mice. Diluted control
blood was incubated with biotinylated rat IgG2a (10 mg/ml; control [ctrl]) or
JAQ1 (10 mg/ml; in vitro) for 6 h at 378C. Subsequently, these samples and
samples from JAQ1-treated mice (ex vivo) were incubated with FITC-
labeled JAQ1 (5 mg/ml), streptavidin (Strep; 5 mg/ml), or convulxin (Cvx; 5
mg/ml) for 15 min at RT and analyzed directly. Platelets were gated by FSC/
SSC characteristics and Fl2 intensity (anti–mouse GPIIb/IIIaPE). (b) Detec-
tion of surface-bound biotinylated DOM1 (anti-GPV) ex vivo. The staining
was performed as described for biotinylated JAQ1. Results in panels a and b
are expressed as mean log Fl1 6 SD (n 5 6). (c) Top: whole platelet proteins were separated by SDS-PAGE under reducing conditions and biotinylated
JAQ1 was detected with HRP-labeled streptavidin/ECL. For detection of GPVI and GPIIIa, the proteins were separated under nonreducing conditions
and immunoblotted with FITC-labeled JAQ1 or EDL1 followed by HRP-labeled rabbit anti-FITC/ECL. (d) Mice were injected with 100 mg Fab frag-
ments of JAQ1 and platelets were analyzed in a Western blot for the presence of GPVI and GPIIIa after 48 h. These platelets did not aggregate in re-
sponse to collagen (50 mg/ml), CRP (30 mg/ml), or Cvx (10 mg/ml), whereas ADP (10 mM) induced normal aggregation.
Figure 6. Reduced adhesion
to collagen and abolished proco-
agulant response of GPVI-
depleted platelets. (a) Platelets
from JAQ1-treated mice (day 7)
bind normal amounts of plasma
vWF in the presence of botrocetin (2 mg/ml; solid line). Bound vWF was detected by
FITC-labeled anti-vWF Abs (10 mg/ml). No binding was detected in the absence of
botrocetin (shaded area). Normal activation of b1-integrins on platelets from JAQ1-
treated mice in response to thrombin (0.1 U/ml). Resting (shaded area) or thrombin ac-
tivated (solid line) platelets were incubated with FITC-labeled 9EG7 (5 mg/ml) for 15
min at RT and analyzed directly. (b) Washed platelets from control or JAQ1-treated
mice (day 7) were incubated in collagen-coated microtiter plates in the presence or ab-
sence of MgCl2 (1 mM)/CaCl2 (1 mM) for the indicated times and adherent platelets
were quantitated fluorimetrically. The data shown are from a single experiment, repre-
sentative of five identical experiments and expressed as the mean of triplicate readings 6
SD. (c) Flow cytometric analysis of annexin V-FITC binding to platelets from control
and JAQ1-treated (day 7) mice activated with a combination of collagen (50 mg/ml)
and thrombin (0.01 U/ml).465 Nieswandt et al.
to collagen was tested in a static assay. As shown in Fig. 6 b,
the adhesion of platelets from JAQ1-treated mice was
strongly reduced as compared with control platelets and
was abolished in the absence of extracellular free magne-
sium/calcium, strongly suggesting it to be mediated pre-
dominantly by integrin a2b1 (34). It is well known that
GPVI is critically involved in the procoagulant response
of platelets where stimulated platelets expose negatively
charged phosphatidylserine (PS) at the plasma membrane
which facilitates thrombin generation (35). Indeed, platelets
from JAQ1-treated mice did not expose PS in response to a
combination of collagen and thrombin on day 3, 7, and 14
after Ab injection, as demonstrated by the lack of annexin
V binding (Fig. 6 c).
Anti-GPVI Treatment Induces Long-term Antithrombotic
Protection but Only Moderately Increased Bleeding Times.
The results of the previous experiments suggested that
JAQ1 specifically induced complete depletion of GPVI in
platelets in vivo. To examine to which extent this specific
defect influenced normal hemostasis, we determined the
tail bleeding times on day 7 after a bolus injection of JAQ1
(100 mg). As shown in Fig. 7, the bleeding times were sig-
nificantly increased in GPVI-depleted mice compared with
control mice (330 6 103 vs. 158 6 89 s, respectively), but
consistently lower than in mice pretreated with 100 mg
blocking F(ab9)2 fragments against GPIIb/IIIa (reference
24;  .600 s). In the next step, we examined the protective
effect of JAQ1 in a model of lethal pulmonary throm-
boembolism induced by infusion of a mixture of collagen
(0.8 mg/kg body weight) and epinephrine (60 mg/kg body
weight; reference 27). Among control mice pretreated with
irrelevant rat IgG2a, 95% (19 of 20) died within 5 min
from widespread pulmonary thrombosis and cardiac arrest.
In contrast, all mice pretreated with JAQ1 (100 mg) sur-
vived, irrespective of whether they had received the mAb
3, 7, or 14 d before challenge (n 5 8 per group; Fig. 8 a).
Figure 7. Bleeding time of JAQ1-treated mice. Bleeding times were
determined in mice 7 d after injection of 100 mg nonimmune IgG2a or
JAQ1 (n 5 15 per group). As a control, mice received 100 mg F(ab9)2
fragments of JON/A (anti-GPIIb/IIIa) 24 h before the experiment (n 5
6). Where necessary, bleeding was manually stopped at the 10 min time
point to prevent death. Each point represents one individual.
Figure 8. JAQ1 induces long-term protection from intravascular thrombosis. Thromboembolism in response to a bolus injection of a mixture of col-
lagen (0.8 mg/kg body weight) and epinephrine (60 mg/kg body weight). (a) Mortality in control mice and mice treated with 100 mg JAQ1 at the indi-
cated times before challenge. (b) Platelet counts in control and JAQ1-treated mice 3 min after infusion of collagen/epinephrine (n 5 8 per group). (c)
Top: representative histology of the lungs (original magnification: 3100); obstructed vessels are indicated by arrowheads. Bottom: immunohistochemical
detection of platelets in the thrombi (original magnification: 3400). Acetone-fixed frozen sections were reacted with a platelet-specific Ab (anti–GPIb-
IX) and counterstained with hematoxylin. The red HRP reaction product shows high density of platelets in the thrombus.466 Long-term Antithrombotic Protection by In Vivo Depletion of GPVI
Although the platelet counts in JAQ1 pretreated mice had
not been influenced significantly by the infusion of col-
lagen/epinephrine, there was a sharp decrease detectable in
control mice (n 5 8) which was determined 3 min after in-
duction of thromboembolism in a separate group (Fig. 8 b).
For histological examination, control and JAQ1 pretreated
(3, 7, and 14 d) mice received the same treatment in paral-
lel experiments but the lungs were removed after 3 min.
Although the vast majority of large and small vessels were
obstructed by platelet rich thrombi in the lungs of control
mice, there were only very few thrombi detectable in the
lungs of JAQ1 pretreated mice (Fig. 8 c).
Discussion
In this study we demonstrate that treatment of mice with
mAb against GPVI results in profound long-term anti-
thrombotic protection against collagen-dependent throm-
boembolism. These results confirm the proposed critical
role of GPVI in collagen-induced activation of platelets in
vivo and indicate that anti-GPVI agents might be effective
in preventing arterial thrombosis induced by atherosclerotic
plaque rupture, where platelets are thought to become acti-
vated mainly by the subendothelium under conditions of
high shear stress (4, 5, 36). Among the matrix proteins
which support platelet adhesion and subsequent activation,
collagen has a critical role, at least in normal hemostasis, as
patients with defects in collagen receptors display mild
bleeding disorders (12, 37, 38). Although the role of GPIb,
GPIIbIIIa, and their respective ligands vWF and fibrinogen
in thrombosis are well documented (for a review by Z.M.
Ruggeri, see reference 39), the finding that vWF and fi-
brinogen double-knockout mice are still able to form oc-
clusive thrombi suggests that collagen and its platelet recep-
tors might also have a critical role in thrombosis (40).
The profound inhibitory effect of JAQ1 in vivo was un-
expected, as it was based on clearing of GPVI from circu-
lating platelets and no such specific depletion of a platelet
receptor has been described to date. The complete loss of
functional GPVI on circulating platelets in JAQ1-treated
mice was confirmed by different approaches. First, the pro-
tein was not detectable in a Western blot analysis of platelet
lysates for at least 2 wk (which exceeds the normal life span
of platelets [41]). Second, the GPVI-specific snake venom
toxin convulxin, which binds to a different epitope than
JAQ1 (Fig. 3, b and c), did not bind to platelets from
JAQ1-treated mice, strongly suggesting the absence of
GPVI from the platelet membrane. Third, an z60-kD
protein with an isoelectric point of z5.6 (which is similar
to that described for human GPVI [42]) is absent in the ly-
sate of platelets from JAQ1-treated mice (Fig. 4), and the
same protein is absent in platelets from FcR g-chain–defi-
cient mice (not shown) which are known to lack GPVI
(15). Most importantly, the functional platelet responses to
collagen were completely abolished by JAQ1 in vivo,
whereas the mAb only has limited inhibitory effects in vitro
(29; Fig. 2 c). These results demonstrate that JAQ1 induced
the clearing of GPVI from the surface of circulating plate-
lets in vivo. This finding is also supported by the observa-
tion that biotinylated JAQ1 was detectable in the lysates,
but not on the surface, of platelets 6 h after injection and
the same was found for GPVI. Furthermore, the decreasing
signals for both GPVI and JAQ1 after 24 and 48 h strongly
suggest that the internalized complex was degraded in the
intracellular compartments. GPVI belongs to the immuno-
globulin superfamily and is closely related to immunore-
ceptors, some of which may become internalized when
stimulated appropriately (43, 44). In the case of JAQ1–
GPVI, it was difficult to define what the appropriate stimu-
lus is, but it seems clear that the Fc part of the mAb is not
required to induce internalization, as Fab fragments pro-
duced the same effect, thereby also excluding the require-
ment for GPVI clustering. In vitro, JAQ1 did not induce
the downregulation of GPVI from the platelet membrane
(Fig. 5 a), suggesting that a second signal may be required
for the induction of this process that is provided by other
cells in vivo. This assumption may be supported by the ob-
servation that JAQ1 and Fab fragments of the mAb induced
transient thrombocytopenia. The reason for this is not
clear, but it might be due to weak activation of GPIIb/IIIa
leading to formation of loose aggregates and their tempo-
rary sequestration to the spleen where the actual loss of
GPVI may occur. Recent evidence indicates that JAQ1
recognizes an epitope identical with or in close vicinity to
the CRP binding site on GPVI (29), which is regarded as
the major binding site for collagen on the receptor. So far,
very little is known about the cellular regulation of GPVI,
but in the light of the current data it seems possible that oc-
cupancy of this epitope provides a signal that finally results
in downregulation of the receptor.
Irrespective of the underlying mechanism, platelets from
JAQ1-treated mice were completely unresponsive towards
activation with high concentrations of CRP or collagen,
whereas they were normally activatable with ADP or
PMA. This strongly suggests that JAQ1 selectively induced
a transient GPVI deficiency in mice, whereas other mem-
brane glycoproteins, including GPIIb/IIIa, GPIb-IX-V,
CD9, and integrin a2b1 were not affected in expression
and/or function. JAQ1-treated mice had prolonged bleed-
ing times, which confirms the important role of GPVI in
normal hemostasis and correlates well with the bleeding di-
athesis in GPVI-deficient patients (12, 22). Very interest-
ingly, one GPVI-deficient patient developed highly specific
Abs against the absent receptor (45) which may be difficult
to explain. However, based on the results presented here it
is feasible to speculate that this patient may suffer from an
acquired GPVI deficiency, based on autoantibody-induced
clearing of GPVI from her circulating platelets.
Besides its pivotal role in collagen-induced platelet acti-
vation, GPVI is also critically involved in the procoagulant
reaction of platelets (46), which was confirmed by the abol-
ished collagen-dependent procoagulant activity of platelets
from JAQ1-treated mice. This result strongly suggests that
anti-GPVI treatment also modulates coagulation at sites of
vascular injury. Such an anticoagulant activity has been
demonstrated for GPIIb/IIIa antagonists (47), which are467 Nieswandt et al.
currently considered the most powerful inhibitors of plate-
let participation in thrombosis (48), as they inhibit the final
common pathway of platelet aggregation irrespective of the
agonist that stimulates the cells. It has been suggested that
this more or less complete inhibition of platelet function
may come with a potential safety risk, as platelet aggrega-
tion is also required for normal hemostasis (49). We found
that JAQ1 induced significantly shorter bleeding times than
blocking Abs against GPIIb/IIIa in mice, indicating that
GPVI-depleted platelets still contributed significantly to
normal hemostasis in vivo. Although there is no clear cor-
relation between the bleeding time and bleeding risk (50),
it is tempting to speculate on the grounds of these results
that anti-GPVI therapy might be associated with a rela-
tively low risk of clinical hemorrhage.
The mechanisms of collagen–platelet interactions are
complex and involve direct or indirect binding of collagen
to several platelet receptors, including the GPIb-IX-V
complex, integrin a2b1, GPIV, GPVI, and 65- and 85-kD
proteins (51). Despite its essential role in collagen-induced
activation of platelets, there has been only very limited evi-
dence for a role of GPVI in adhesion to collagen (17),
which is mainly thought to be mediated by GPIb-IX-V
(via vWf) and integrin a2b1. In mice, GPVI-depleted
platelets expressed normal amounts of integrin a2b1, and
b1-integrins were normally activatable, which has been re-
ported to be a prerequisite for effective binding of collagen
(52; Fig. 6 b). Indeed, GPVI-depleted platelets adhered to
collagen through a2b1, but the extent of adhesion was
strongly reduced compared with control platelets. A similar
observation has been reported with platelets from GPVI-
deficient patients (12, 45), indicating that GPVI may be re-
quired for normal adhesion to collagen probably by sup-
porting the activation of a2b1 (53).  The expression of
GPIb-IX-V was not affected by the JAQ1 treatment and
the receptor bound normal levels of vWF in the presence
of botrocetin (Fig. 6 a). Together, these results suggest that
platelet adhesion to collagen at sites of vascular injury may
be reduced, but not blocked, by anti-GPVI treatment.
Very recent evidence suggests that GPVI is exclusively
expressed in platelets and mature megakaryocytes (17, 54),
and this is confirmed by immunohistochemical studies with
JAQ1 (not shown). Therefore, the effects of anti-GPVI
agents (like JAQ1) should be restricted to platelets and,
very importantly, megakaryocytes. JAQ1 was detectable on
megakaryocytes in spleen and bone marrow 3 h after Ab
injection (not shown), suggesting that the next generation
of platelets was also affected by the mAb. This assumption
may be confirmed by the fact that GPVI was not detectable
in platelets for at least 2 wk, although the normal life span
of mouse platelets is only z4–5 d (41). Based on the esti-
mated number of z2  3 109 platelets/mouse (109/ml
blood) and a life span of the cells of 5 d, the GPVI mole-
cules of 6 3 109 platelets must be depleted to result in the
absence of the receptor for 15 d. The amount of 100 mg
JAQ1 (mol wt: 150 kD) represents z6.7 3 1013 Ab mole-
cules. Therefore, z1.1 3 104 Ab molecules per platelet are
available to bind and deplete GPVI. As the estimated ex-
pression rate of GPVI is only 1–2 3 103 copies/platelet
(55), 100 mg JAQ1 is sufficient to induce the observed ef-
fect.
Preliminary results show that a second injection of JAQ1
2 wk after the first injection has no influence on platelet
counts, but prolongs the absence of GPVI on circulating
platelets (not shown). This indicates that the second dose of
the mAb affects newly differentiated megakaryocytes, but
has no effect on circulating (GPVI-depleted) platelets.
Thus, JAQ1 can be used to induce a GPVI knock out–like
phenotype in mice for several weeks, allowing studies on
platelet function in the absence of this critical activating re-
ceptor in vitro and in vivo.
Taken together, the results presented here indicate that
GPVI might become an interesting target for long-term
prophylaxis of ischemic cardiovascular diseases and provide
the first evidence that it is possible to specifically deplete an
activating glycoprotein receptor from circulating platelets
in vivo. These findings may open the way for the develop-
ment of a new generation of powerful, yet safe, antithrom-
botics.
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